Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

The summary for the Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed): The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.
Federal Grant Title: Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education, Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-20-314
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.394
CFDA Descriptions: Information not provided
Current Application Deadline: October 10th, 2023
Original Application Deadline: October 10th, 2023
Posted Date: October 13th, 2020
Creation Date: October 13th, 2020
Archive Date: November 15th, 2023
Total Program Funding:
Maximum Federal Grant Award: $250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: October 13th, 2020
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-20-314.html
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensit...
Glioblastoma Therapeutics Network (U19 Clinical Trial Required)
Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Clinic...
Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)
Image-Guided Cancer Interventions (STTR [R41/R42])
An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)
In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2020 FederalGrants.com